Immunic (NASDAQ:IMUX) Stock Rating Upgraded by Zacks Research

Key Points

• Zacks Research upgraded Immunic to “strong buy” from “hold,” though analyst opinions remain mixed. MarketBeat’s consensus rating is “Buy,” with an average price target of $35.43.
• Immunic shares opened at $7.22, below their 50-day moving average of $11.23 and 200-day moving average of $12.52. The stock has traded between $5.06 and $17.43 over the past year.
• The clinical-stage biotechnology company reported quarterly EPS of -$0.80, beating expectations of -$1.16, while institutional investors own 51.82% of its shares. Its lead drug candidate, vidofludimus calcium, is being tested for multiple sclerosis.

Immunic (NASDAQ:IMUX - Get Free Report) was upgraded by investment analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research note issued on Wednesday, Zacks reports.

Several other research analysts have also issued reports on IMUX. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunic in a research note on Wednesday, August 26th. LADENBURG THALM/SH SH raised shares of Immunic to a "strong-buy" rating in a research note on Wednesday, July 29th. Wall Street Zen lowered shares of Immunic from a "hold" rating to a "sell" rating in a research note on Saturday, October 10th. HC Wainwright restated a "buy" rating and issued a $22.00 price objective on shares of Immunic in a report on Thursday, September 10th. Finally, Wedbush reaffirmed an "outperform" rating and set a $45.00 target price on shares of Immunic in a research note on Thursday, September 10th. Four research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Immunic has a consensus rating of "Buy" and a consensus target price of $35.43.

Immunic Stock Down 3.5%

Shares of IMUX stock opened at $7.22 on Wednesday. The business's fifty day moving average is $11.23 and its 200 day moving average is $12.52. Immunic has a twelve month low of $5.06 and a twelve month high of $17.43.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.36. Analysts forecast that Immunic will post -3.71 EPS for the current fiscal year.

Institutional Trading of Immunic

A number of institutional investors and hedge funds have recently bought and sold shares of IMUX. Braidwell LP purchased a new stake in Immunic during the 2nd quarter valued at $9,914,000. OMERS ADMINISTRATION Corp purchased a new position in Immunic in the 1st quarter worth about $187,000. Bank of America Corp DE lifted its stake in Immunic by 80,724.2% during the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company's stock valued at $160,000 after acquiring an additional 143,689 shares during the period. Renaissance Technologies LLC bought a new position in Immunic during the 1st quarter valued at about $1,020,000. Finally, Avidity Partners Management LP lifted its stake in Immunic by 42.6% during the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company's stock valued at $7,436,000 after acquiring an additional 2,000,000 shares during the period. 51.82% of the stock is currently owned by institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic's lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.